Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
HXK II Lentiviral Activation Particles (h): sc-400611-LAC
- Target species: human
- 200 µl of transduction-ready, high-titer CRISPR/dCas9 Lentiviral Activation Particles
- HXK II Lentiviral Activation Particles (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically and efficiently upregulate gene expression via lentiviral transduction of cells
- HXK II Lentiviral Activation Particles (h) contain the following SAM Activation elements: a deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, an MS2-p65-HSF1 fusion protein and a target-specific 20 nt guide RNA. They also contain the blasticidin, hygromycin and puromycin resistance genes
- Upon transduction, the SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by HXK II Lentiviral Activation Plasmid (h) and HXK II Lentiviral Activation Plasmid (h2) target distinct regulatory regions of the HK2 promoter. One or both designs may be available
- Following transfection, gene activation efficiency can be assayed by WB, IF or IHC using antibody: HXK II Antibody (B-8): sc-374091
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
HXK II Lentiviral Activation Particles (h) | sc-400611-LAC | 200 µl | $455.00 |
Human HK2 encodes hexokinase II (HXK II), the mitochondrial-associated enzyme that catalyzes the ATP-dependent phosphorylation of glucose to glucose-6-phosphate, committing glucose to glycolysis and downstream anabolic pathways. By linking glucose utilization to mitochondrial metabolism, HXK II supports glycolytic flux, pentose phosphate pathway entry, and metabolic adaptations during hypoxia through integration with HIF-1 signaling and PI3K–AKT–mTOR-regulated programs. HK2 activity is frequently associated with metabolic reprogramming in proliferative states, where elevated glycolysis and altered redox handling influence cell survival and biosynthetic capacity. As a result, HK2/HXK II is broadly used as a mechanistic node for studying glucose sensing, mitochondrial–metabolic coupling, and disease-relevant metabolic phenotypes in human cells.
HXK II Lentiviral Activation Particles (h) address this need by packaging the complete synergistic activation mediator (SAM) transcriptional activation system into transduction-ready, high-titer lentiviral particles, enabling efficient HK2 upregulation across a broader range of human cell types.
HXK II Lentiviral Activation Particles (h) deliver all functional components of the synergistic activation mediator (SAM) system via lentiviral transduction. The system comprises three particle preparations co-transduced into target cells: one encoding catalytically inactive dCas9 (D10A and N863A mutations) fused to the VP64 transactivation domain with a blasticidin resistance gene; one encoding the MS2-p65-HSF1 fusion protein with a hygromycin resistance gene; and one encoding a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers with a puromycin resistance gene. Following lentiviral transduction and genomic integration of the expression cassettes, the SAM components are stably expressed and assemble at the target locus within the proximal promoter region upstream of the HK2 transcriptional start site, where VP64, p65, and HSF1 act cooperatively to recruit endogenous transcriptional machinery and drive sustained upregulation of endogenous HXK II expression. The use of nuclease-inactive dCas9 avoids the introduction of double-strand DNA breaks and preserves the native HK2 genomic locus and regulatory architecture.
The lentiviral format offers several practical advantages: stable genomic integration supports heritable activation across cell divisions; high-titer particle preparations eliminate the need for in-house viral production; and compatibility with primary, non-dividing, and transfection-resistant cell types expands experimental accessibility. Successful transduction can be confirmed and enriched through triple antibiotic selection using puromycin, hygromycin, and blasticidin.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.